Please login to the form below

Not currently logged in
Email:
Password:

Recordati acquires AstraZeneca blood pressure brands

Italian pharma firm obtains Seloken and Logimax

RecordatiRecordati has picked up the rights to two of AstraZeneca’s hypertension treatments as part of a $300m (€270m) deal.

The agreement sees the Milan-based pharmaceutical group acquire rights to AZ’s Seloken ZOK (metoprolol succinate) and Logimax fixed dose combination (metoprolol succinate and felodipine) treatments in Europe.

Metoprolol is a beta-blocker used mainly for conditions such as hypertension, angina pectoris and heart disorders.

Although both brands have been on the market for more than a decade, they still brought in around €100m last and Recordati is hoping they will help “reinforce its product portfolios in a number of its European subsidiaries, in particular Poland, France and Germany”.

The deal is expected to be completed in the coming weeks, after which AZ will be in-line for some additional royalties on the brands.

Andrea Recordati, vice chairman and CEO of Recordati, said: “We are very pleased with the agreement that we have entered into with AstraZeneca for the rights of their brands of metoprolol in Europe. Existing sales of the metoprolol brands will provide the base to enter new markets and thus complete our European geographical footprint.

“This new significant addition to our portfolio will strengthen our position in the European market and contribute to a further enhancement of our profitability margins.”

The with Recordati is the latest effort in AZ’s slimming drive, which has already seen it divest a number of non-core products to free up cash for its R&D plans.

Article by
Gemma Jones

25th May 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics